Dr. Joshua W. Russo, MD, PhD, is an Instructor in Medicine at Harvard Medical School and a Staff Scientist in the Division of Hematology/Oncology at Beth Israel Deaconess Medical Center. An early-career physician-scientist, he is a member of the Balk Lab, where his research on advanced prostate cancer earned him a 2018 Young Investigator Award from the Prostate Cancer Foundation.
His scientific interests focus on elucidating the molecular mechanisms of resistance to second-line androgen deprivation therapies, specifically abiraterone and enzalutamide, in castration-resistant prostate cancer (CRPC). His current research includes investigating:
- DPP4 Downregulation: Establishing how the downregulation of the cell-surface dipeptidase DPP4 drives therapy resistance and increases receptor tyrosine kinase (RTK) signaling.
- ErbB2 Signaling: Interrogating the role of ErbB2/ErbB3 signaling and specific ErbB2 splice variants in tumor progression.